TBI‑001: A TRIB2‑Targeted Strategy to Counter Lineage Plasticity and Treatment‑Emergent Neuroendocrine Prostate Cancer

A new experimental drug called TBI‑001 targets a protein called TRIB2 in advanced prostate cancer that has become resistant to hormone therapy and starts acquiring neuroendocrine features. This is particularly relevant for treatment‑emergent neuroendocrine prostate cancer (t‑NEPC), a lethal subtype that arises after long‑term androgen‑receptor–targeted therapy, loses dependence on AR signaling, and adopts a neuroendocrine or lineage‑plastic identity associated with rapid progression, visceral metastasis, and poor survival. In t‑NEPC, TRIB2 is often overexpressed and acts as a central hub that links resistance to enzalutamide with the activation of neuroendocrine programs and survival pathways, making it an attractive node for intervention.

TBI‑001 is a small‑molecule inhibitor designed to bind TRIB2 directly and induce its degradation through the ubiquitin–proteasome system. By removing TRIB2, the drug disrupts multiple downstream pathways at once, including AKT and BCL2, which are key mediators of survival and therapy resistance in prostate cancer. At the transcriptional and epigenetic level, TBI‑001 broadly suppresses the gene programs that TRIB2 helps maintain, reducing expression of regulators such as EZH2 and BRD4, stemness and plasticity factors such as SOX2 and N‑MYC, and canonical neuroendocrine transcription factors such as ASCL1 and BRN2. It also lowers levels of established neuroendocrine markers including DLL3 and PEG10, which are hallmarks of aggressive neuroendocrine tumors.

Crucially, TBI‑001 reduces CD56 (NCAM1), a surface marker strongly associated with neuroendocrine differentiation, lineage plasticity, metastasis, and immune evasion in t‑NEPC. It also decreases B7‑H3 (CD276), an immune‑modulatory molecule that contributes to an immunosuppressive microenvironment and is often upregulated in aggressive prostate cancers. These changes suggest that inhibiting TRIB2 not only blunts neuroendocrine programs but may also make the tumor less able to hide from the immune system. In functional assays, TBI‑001 potently reduces viability and induces apoptosis in antiandrogen‑resistant prostate cancer cells and in neuroendocrine models such as NCI‑H660 and LASCPC‑01, while exerting only mild effects on normal epithelial cells, indicating a therapeutic window.

In xenograft models that mimic therapy‑resistant, neuroendocrine‑like prostate cancer, TBI‑001 produces significant tumor regression rather than mere stabilization, accompanied by reduced expression of CD56, ASCL1, BRN2, DLL3, and other neuroendocrine markers. At efficacious doses, no overt toxicity is observed, and metabolic profiling in human hepatocytes shows favorable hepatic metabolism and stability, supporting the possibility of oral dosing and predictable exposure in patients. These properties position TBI‑001 as one of the first purpose‑designed TRIB2‑targeted agents with a pharmacologic profile that could be suitable for clinical development.

Source.